Swiss Medical Weekly Chooses Xpublisher for JATS XML-Based Publications
28.2.2023 17:09:00 EET | Business Wire | Press release
Xpublisher is the new publishing system for medical journal Swiss Medical Weekly (SMW). Working with Xpublisher enables SMW to publish JATS XML-based scientific articles online swiftly and reliably.
Swiss Medical Weekly uses Xpublisher
By choosing Xpublisher, the journal is pursuing a consistent XML and content-first approach to preparing media-independent content and automating its publication. The software’s integrated Xeditor assists the editorial team in formatting scientific articles based on the JATS XML article authoring schema. Xpublisher then facilitates a conversion of the XML data, customized for SMW, into an HTML format, which SMW uses for online publication through the CMS "Open Journal Systems" (OJS). “In parallel with migrating our website to Open Journal Systems, we were very interested in establishing an XML-first workflow based on the JATS format. We have analyzed several solutions and are absolutely convinced by Xpublisher and Xeditor. With the help of the Xpublisher GmbH team, we designed a customized system that clearly maps our processes and helps us to create all our articles in valid JATS XML. Since Xpublisher provided a JATS format, we not only imported the content, we also imported the metadata of every single previous article in our extensive archive into OJS completely automatically,” reports a pleased Dr. Natalie Marty, managing director of the SMW supporting association. The Xpublisher editorial system is available as SaaS in a highly secure cloud environment.
About Swiss Medical Weekly
Founded in 1871, the Swiss Medical Weekly is a medical journal with a long tradition. The SMW is a pioneer of the Diamond Open Access model. Even before the publication of the Berlin Declaration on Open Access, the journal had already introduced free open online access to all published articles, without charging authors publication fees. The articles are reviewed according to strict scientific criteria and published regularly online. The journal is published by the non-profit organization “Trägerverein Swiss Medical Weekly,” which aims to enable and advance publishing based on the Diamond model. For more information, visit www.smw.ch.
About Xpublisher GmbH
Xpublisher GmbH is a leading provider in the multichannel publishing space, delivering intuitive products for creating, managing, and automating magazine, book, and documentation publishing with Xeditor and Xpublisher. Xpublisher was founded in 2009 and is based in Munich, Germany. The company operates a US subsidiary and has been part of the Fabasoft Group since 2019. Numerous leading international companies and organizations in the publishing, aerospace, technology, education, and public administration sectors together with a host of other industries have already placed their trust in Xpublisher’s products.
For more information, visit www.xpublisher.com or follow us on LinkedIn and Twitter @Xpublisher.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005220/en/
Contact information
Press contact
Julia Schnelldorfer
+49 162 2166891
julia.schnelldorfer@xpublisher.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vensica Medical Receives FDA IND Clearance to Initiate Phase 2 Study of ViXe, Its Needle-Free Xeomin ® Delivery System for Overactive Bladder28.4.2026 15:42:00 EEST | Press release
Vensica Medical, a clinical-stage company developing needle-free therapeutic delivery solutions for urologic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of ViXe. The study will evaluate the Vibe® ultrasound-based, needle-free drug delivery system in combination with Xeomin® (incobotulinumtoxinA) for the treatment of overactive bladder (OAB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414145279/en/ Avner Geva, Cofounder, CEO (left), and Avi Eftel, Cofounder, CTO (right) Overactive bladder affects an estimated 33 million adults in the United States and is characterized by urinary urgency, frequency, and incontinence. While intravesical botulinum toxin injection is an established second-line treatment, the invasive procedure limits patient access and acceptance. The ViXe program is desi
Printing the Future of Oncology: CTIBIOTECH Invests €3M and Secures €1.25M from France 2030 to Revolutionize Personalized Cancer Care28.4.2026 15:28:00 EEST | Press release
CTIBIOTECH Announces the CTIONCOTEST ™ Project to Revolutionize Cancer Research with 3D Bioprinted Microtumors, Backed by France 2030 and Bpifrance This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428242352/en/ The CTIONCOTEST™ platform by CTIBIOTECH is an innovative 3D bioprinting technology that revolutionizes preclinical cancer research . It provides an automated, industrial-scale process to produce high-throughput, patient-specific human "microtumors" directly from primary tumor cells . Designed to tackle the 95% clinical failure rate of new cancer drugs, it faithfully replicates the complex tumor microenvironment, including critical hypoxic and necrotic zones . Targeting high-mortality breast, colon, and pancreatic cancers, the platform features three complexity levels: standard (cancer cells), intermediate (+fibroblasts), and advanced (+immune/endothelial cells) . A key breakthrough is its record cellular viability of
BMG and Concord Combine to Create World’s Leading Independent Music Company28.4.2026 15:11:00 EEST | Press release
BMG and Concord today announced a definitive agreement to combine their businesses, creating the leading independent music company in the world. Operating under the BMG name, the combined company will bring together two highly complementary businesses to establish a scaled, global company delivering superior service to artists, songwriters, and partners – firmly grounded in an independent, artist-first model. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427537841/en/ Thomas Coesfeld and Bob Valentine, Courtesy of BMG and Concord The combination comes amid significant transformation in the global music market, where scale, global reach, and technology investment are increasingly critical to remain competitive. Together, BMG and Concord will form a fully integrated global music company spanning music publishing, recorded music, theatrical rights, and digital distribution. This increased scale will enable deeper investment
Masimo SET ® Pulse Oximetry Performed Accurately on Hospitalized Newborns of All Skin Tones in Largest-Ever Prospective Real-World Study28.4.2026 15:00:00 EEST | Press release
Masimo (NASDAQ: MASI) today announced the findings of a study evaluating the accuracy of Masimo SET® pulse oximetry among critically ill neonates and demonstrating less than 1% overall statistical bias. Importantly, there were no clinically meaningful skin pigmentation-related discrepancies and no occult hypoxemic events among Black or Hispanic patients, and in only one Caucasian patient overall. The Neonatal Pulse Oximetry Accuracy and Disparities by Skin Pigmentation (NeoPODS) study findings were presented from the podium at the Pediatric Academic Society in Boston, MA on Monday, April 27th at 10 am EST by lead author Dr. Heather Siefkes on behalf of colleagues at the University of California, Davis and the University of Mississippi, Jackson, alongside online publication in the Journal of Pediatrics. As the authors noted, “[W]e found no evidence of clinically meaningful skin tone-related discrepancies, suggesting equitable monitoring performance for this device in this clinical setti
KAYTUS AI Compute Pod Wins 2026 iF Design Award and Red Dot Award, Setting a New Standard for AI Data Center28.4.2026 12:54:00 EEST | Press release
KAYTUS, a leading provider in AI infrastructure and liquid-cooling solutions, announced that its AI Compute Pod has received both the 2026 iF Design Award and Red Dot Award. This dual recognition not only stems from its outstanding performance in green, low-energy operation—achieving up to 130 kW cooling capacity per rack and a PUE as low as 1.1 through optimized thermal and power design—but also from its innovative approach to intelligent control and efficient O&M. The solution enables second-level synchronization between cooling and IT workloads, and leverages a dual-group control strategy to improve cooling energy efficiency by over 10%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428825343/en/ KAYTUS AI Compute Pod Wins 2026 iF Design Award and Red Dot Award, Setting a New Standard for AI Data Center Jury panels from both awards highlighted the AI Compute Pod's excellence in miniaturization, modularity, and intelli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom